Soligenix, Inc. (NASDAQ:SNGX) Short Interest Update

Soligenix, Inc. (NASDAQ:SNGX) was the recipient of a significant decline in short interest in October. As of October 31st, there was short interest totalling 47,100 shares, a decline of 64.9% from the October 15th total of 134,300 shares. Currently, 2.1% of the shares of the stock are sold short. Based on an average daily volume of 135,700 shares, the short-interest ratio is presently 0.3 days.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of the company. Armistice Capital LLC acquired a new position in Soligenix in the second quarter worth approximately $206,000. Stephens Inc. AR bought a new stake in shares of Soligenix during the 3rd quarter worth $184,000. Finally, OLD National Bancorp IN acquired a new position in shares of Soligenix in the 2nd quarter worth $26,000. 3.60% of the stock is owned by institutional investors and hedge funds.

Soligenix Stock Performance

NASDAQ SNGX traded down $0.02 on Wednesday, reaching $3.63. 11,987 shares of the stock traded hands, compared to its average volume of 848,014. Soligenix has a 12 month low of $1.83 and a 12 month high of $32.00. The firm’s fifty day simple moving average is $3.78 and its 200 day simple moving average is $4.37.

About Soligenix

Soligenix, Inc, a late-stage biopharmaceutical company, focuses on developing and commercializing products to treat rare diseases in the United States. The company operates through two segments, Specialized BioTherapeutics and Public Health Solutions. The Specialized BioTherapeutics segment develops SGX301 (HyBryte), a novel photodynamic therapy, which has completed Phase III clinical trial for the treatment of cutaneous T-cell lymphoma; SGX942, an innate defense regulator technology that is in Phase III clinical trial for the treatment of inflammatory diseases, including oral mucositis in head and neck cancer; SGX302, an IDR technology which is in Phase IIa study to treat mil-to-moderate Psoriasis; and SGX945 and IDR technology that is in Phase IIa protocol for the treatment of Aphthous Ulcers in Behçet's Disease.